← feed

Is NCT03213145 results overdue?

Yes — results are overdue. Primary completion was 2017-08-10; the FDAAA-801 reporting deadline (2018-08-10) passed 2872 days ago and no results are posted on ClinicalTrials.gov.

Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers

NCT IDNCT03213145 ↗
SponsorEnanta Pharmaceuticals, Inc (INDUSTRY)
Public issuerENANTA PHARMACEUTICALS INC — ENTA (CIK 0001177648) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-08-10 (ACTUAL)
Reporting deadline2018-08-10 (completion + 365d)
Days overdue2872
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 558a965a971dee1d… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03213145. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →